These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 18535046)
1. US branded drug makers pay to prevent generic competition. Tanne JH BMJ; 2008 Jun; 336(7656):1266-7. PubMed ID: 18535046 [No Abstract] [Full Text] [Related]
2. The impact of generic goods in the pharmaceutical industry. Ferrándiz JM Health Econ; 1999 Nov; 8(7):599-612. PubMed ID: 10544326 [TBL] [Abstract][Full Text] [Related]
3. Angst about exclusivity: The potential cost of incentivizing makers of generic drugs. Chakradhar S; Khamsi R Nat Med; 2017 Oct; 23(10):1114-1116. PubMed ID: 28985215 [No Abstract] [Full Text] [Related]
4. A shift on "pay for delay"--reopening doors for pharmaceutical competition? Hemphill Kraus EJ N Engl J Med; 2012 Nov; 367(18):1681-3. PubMed ID: 23113478 [No Abstract] [Full Text] [Related]
5. The Eleventh Circuit holds that agreements in which pharmaceutical companies pay generic companies not to compete may be valid. Garrigues A J Law Med Ethics; 2004; 32(1):181-4. PubMed ID: 15152443 [No Abstract] [Full Text] [Related]
6. Regulators can challenge deals that delay generic competition, says US Supreme Court. McCarthy M BMJ; 2013 Jun; 346():f3964. PubMed ID: 23783361 [No Abstract] [Full Text] [Related]
8. Using a drug-safety tool to prevent competition. Sarpatwari A; Avorn J; Kesselheim AS N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666 [No Abstract] [Full Text] [Related]
9. Addressing Generic-Drug Market Failures - The Case for Establishing a Nonprofit Manufacturer. Liljenquist D; Bai G; Anderson GF N Engl J Med; 2018 May; 378(20):1857-1859. PubMed ID: 29768140 [No Abstract] [Full Text] [Related]
10. Branded drug reformulation: the next brand vs. generic antitrust battleground. Amoresano GV Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032 [No Abstract] [Full Text] [Related]
11. The new drug war. Sherrid P US News World Rep; 2002 Dec; 133(21):41. PubMed ID: 12503485 [No Abstract] [Full Text] [Related]
12. Possible anticompetitive agreements between brand, generic companies to be studied. Landis NT Am J Health Syst Pharm; 2000 Dec; 57(23):2140, 2142. PubMed ID: 11127691 [No Abstract] [Full Text] [Related]
13. Delaying generic competition--corporate payoffs and the future of Plavix. Shuchman M N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945 [No Abstract] [Full Text] [Related]
17. Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. Jones GH; Carrier MA; Silver RT; Kantarjian H Blood; 2016 Mar; 127(11):1398-402. PubMed ID: 26817958 [TBL] [Abstract][Full Text] [Related]
18. [Blocking of generic drugs must be fought]. Kringlen E Tidsskr Nor Laegeforen; 2013 Oct; 133(19):2032. PubMed ID: 24129531 [No Abstract] [Full Text] [Related]
19. The U.S. Medicine Chest: Implications of Increased Reliance on China. Gibson R Ann Intern Med; 2018 Dec; 169(12):873-874. PubMed ID: 30535133 [No Abstract] [Full Text] [Related]
20. Congress works to permit 'biosimilar' drugs very soon. Carroll J Manag Care; 2009 Apr; 18(4):7-8. PubMed ID: 19472559 [No Abstract] [Full Text] [Related] [Next] [New Search]